NPPB and Sepsis: An ongoing clinical trial that uses AngII as a vasopressor in patients with sepsis will clarify whether AngII treatment itself and the anticipated partial improvement of arterial pressure will suffice to correct tissue perfusion or whether combined treatment with other interventions that can also increase arterial pressure, such as BNP suppression, is warranted.